Business Wire - Thursday, June 3, 1999
"I am very interested in examining Immune Response Corp.'s conclusion of their Phase III HIV vaccine trials. This was done on the recommendation of an Independent Data Safety Monitoring Board (DSMB)," Dr. Skinner said. "We will be requesting detailed, unprocessed information on these trials from the DSMB to help us further our development of our HIV-VAC vaccine which will begin clinical trials within six to nine months."
HIV-VAC's HIV vaccine was developed by Dr. Skinner at the University of Birmingham, United Kingdom. It has been under development for the last 10 years. Toxicity trials are almost completed.
Dr. Skinner added, "The HIV-VAC vaccine is expected to prevent the disease, and also may prevent the onset of AIDS in HIV-positive patients. Many scientists have been working on a vaccine for AIDS over the last 10 years. We have developed a new approach to the AIDS problem through the creation of an intracellular vaccine based on technology proven in clinical trials with herpes genitalis and pre-clinical research into cytomegalovirus and equine herpes vaccines."
The HIV-VAC patented intracellular vaccine approach includes gp120/160 and uses core proteins p55, p24, p17 and others. The multi-protein approach used by HIV-VAC covers the whole spectrum of HIV virus proteins and is believed to offer a rational approach both as a vaccine and for therapeutic purposes. Because the HIV-VAC vaccine proteins are harvested from virus particles and from intracellular virus-coded proteins, the entire spectrum of virus proteins is available for presentation to the immune system.
The United Nations estimates that there are currently 30.6 million people infected worldwide with the AIDS virus. The disease is spreading at a rate of 10,000 people each day. It is estimated that the number of people infected with the AIDS virus by the end of the year 2000 will be 55 million.
The statements contained in this release which are not historical facts contain forward-looking information with respect to plans, projections or future performance of the company; the occurrence of which involves certain risks and uncertainties that could cause the company's actual results to differ materially from expected results. Such risks include the timing of implementation and the scope and success of the program described here.
--30--mj/ny* nmb
CONTACT: HIV-VAC, Toronto K. Jelsing, Investor Relations 877/778-7731 or For Live Interview: www.wallstreetinterview.com
990603
BW990601
Copyright © 1999 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .